Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Feb 14, 2024 06:31PM Form SC 13G/A Applied Therapeutics Filed by: ORBIMED ADVISORS LLC
Feb 14, 2024 04:14PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 13, 2024 08:00AM BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
Feb 12, 2024 11:08AM TRAWSFYNYDD THERAPEUTICS RECEIVES APPROVAL FOR THE FIRST PATIENT TRIAL OF TRX01, A ONCE-DAILY PROTEASE INHIBITOR FOR THE TREATMENT OF COVID 19
Feb 7, 2024 06:00AM Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies
Feb 5, 2024 04:49PM Form SC 13D/A CalciMedica, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 5, 2024 04:42PM Form SC 13D ArriVent Biopharma, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 29, 2024 04:56PM Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 25, 2024 08:41PM Form 3 ArriVent Biopharma, Inc. For: Jan 25 Filed by: ORBIMED ADVISORS LLC
Jan 25, 2024 04:26PM Form SC 13D/A Edgewise Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jan 8, 2024 06:41AM Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company
Dec 29, 2023 04:16PM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Dec 27, 2023 05:03PM Form 144 ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Dec 27, 2023 05:01PM Form 144 ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Dec 27, 2023 04:43PM Form SC 13D/A Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 06:18PM Form 144/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 06:15PM Form 144/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 06:12PM Form 144/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 15, 2023 04:49PM Form SC 13D/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 13, 2023 05:20PM Form SC 13D/A Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 12, 2023 05:59PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 12, 2023 05:53PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 12, 2023 05:42PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 6, 2023 04:44PM Form SC 13D/A SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
Dec 4, 2023 03:46PM Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Conference
Nov 29, 2023 04:21PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Nov 27, 2023 05:29PM Form 144 Apollomics Inc. Filed by: OrbiMed Advisors II Ltd
Nov 27, 2023 06:30AM Theseus Pharmaceuticals (THRX) Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital and OrbiMed Advisors; Unsolicited Proposal from Concentra Biosciences
Nov 27, 2023 06:30AM Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
Nov 24, 2023 04:28PM Form SC 13D/A Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Nov 22, 2023 04:07PM Form 144 PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Nov 20, 2023 04:22PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Nov 17, 2023 08:28AM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
Nov 16, 2023 04:34PM Form 144 Apollomics Inc. Filed by: OrbiMed Advisors II Ltd
Nov 14, 2023 08:53PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
Nov 14, 2023 05:25PM Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
Nov 13, 2023 08:55AM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Nov 10, 2023 07:44AM NanoSyrinx appoints Anthony Johnson as Non-Executive Director
Nov 1, 2023 05:09PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Oct 30, 2023 08:20PM Form 144 Apollomics Inc. Filed by: OrbiMed Advisors Ltd
Oct 5, 2023 05:19PM Form 144 Apollomics Inc. Filed by: OrbiMed Advisors Ltd
Oct 4, 2023 05:37PM Form 4 NeuroPace Inc For: Oct 02 Filed by: ORBIMED ADVISORS LLC
Oct 4, 2023 04:27PM Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
Oct 2, 2023 09:54PM Form 144 Galecto, Inc. Filed by: OrbiMed Advisors Israel II Ltd
Oct 2, 2023 09:51PM Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Oct 2, 2023 09:50PM Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Oct 2, 2023 08:47PM Form 144 NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
Oct 2, 2023 04:41PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Sep 21, 2023 04:53PM Form SC 13D/A Ikena Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 19, 2023 08:00AM ReCode Therapeutics Announces Closing of Extension to Series B Financing

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed